中心性浆液性脉络膜视网膜病变治疗研究进展

杨 悦荣1, 顾朝 辉*2
1、承德医学院;保定市第一中心医院
2、保定市第一中心医院

摘要


中心性浆液性脉络膜视网膜病变（CSC）是中青年常见的黄斑渗出性疾病，多数自限，但反复或慢性可致
视功能永久损害。本文综述重点总结微脉冲激光、光动力治疗、抗VEGF药物、口服药物等主要治疗手段的适应证、
疗效与局限，并简要介绍中医药及联合治疗的应用现状。

关键词


中心性浆液性脉络膜视网膜病变；治疗方法

全文:

PDF


参考


[1]Fung AT, Yang Y, Kam AW. Central serous

chorioretinopathy: a review. Clin Exp Ophthalmol. 2023;

51(2): 243-270. doi:10.1111/ceo.14201.

[2]van Rijssen TJ, De Jong JH, Meijer OC, et al.

Central serous chorioretinopathy: towards an evidence-based

treatment guideline. Prog Retin Eye Res. 2021; 84:100955.

doi:10.1016/j.preteyeres.2021.100955.

[3]Liu B, Deng T, Zhang J. Risk factors for central

serous chorioretinopathy: a systematic review and meta_xfffe_analysis. Retina. 2016; 36(1): 9-19. doi:10.1097/

IAE.0000000000000837.

[4]Sesar A, Pusić Sesar A, Jurišić D, et al. Unraveling

the puzzle of central serous chorioretinopathy: exploring

psychological factors and pathophysiological mechanisms. Med

Sci Monit. 2023; 29:e941216. doi:10.12659/MSM.941216.

[5]Gawęcki M, Jaszczuk A, Grzybowski A. Short-term

presence of subretinal fluid in central serous chorioretinopathy

affects retinal thickness and function. J Clin Med. 2020; 9(11):

3429. doi:10.3390/jcm9113429.

[6]Breukink MB, Downes SM, Sim D, et al. Chronic

central serous chorioretinopathy: long-term follow-up and

vision-related quality of life. Br J Ophthalmol. 2021; 105(4):

550-555. doi:10.1136/bjophthalmol-2020-316734.

[7]Jayakumar K, Bansal S, Markan A, et al. Reversibility

of retinochoroidal vascular alteration in patients with

obstructive sleep apnea after continuous positive air pressure

and surgical intervention. Indian J Ophthalmol. 2021; 69(7):

1850-1855. doi:10.4103/ijo.IJO_3150_20.

[8]Gawecki M, Pytrus W, Swiech A, Mackiewicz

J, Lytvynchuk L. Laser treatment of central serous

chorioretinopathy— an update. Klin Monbl Augenheilkd.

2024; 241(11): 1207-1223. doi:10.1055/a-2338-3235.

[9]Wu Z, Wang H, An J. Comparison of the efficacy

and safety of subthreshold micropulse laser with photodynamic

therapy for the treatment of chronic central serous

chorioretinopathy: a meta-analysis. Medicine (Baltimore).

2021; 100(17): e25722. doi:10.1097/MD.0000000000025722.

[10]Desmettre T, Maurage CA, Mordon S. Heat

shock protein hyperexpression on chorioretinal layers after

transpupillary thermotherapy. Invest Ophthalmol Vis Sci.

2001; 42(12): 2976-2980.

[11]Manayath GJ, Karandikar SS, Narendran S, et

8

al. Low fluence photodynamic therapy versus graded

subthreshold transpupillary thermotherapy for chronic central

serous chorioretinopathy: results from a prospective study.

Ophthalmic Surg Lasers Imaging Retina. 2017; 48(4): 334-

338. doi:10.3928/23258160-20170329-08.

[12]Schlötzer-Schrehardt U, Viestenz A, Naumann

GO, et al. Dose-related structural effects of photodynamic

therapy on choroidal and retinal structures of human eyes.

Graefes Arch Clin Exp Ophthalmol. 2002; 240(9): 748-757.

doi:10.1007/s00417-002-0517-4.

[13]Lai FH, Ng DS, Bakthavatsalam M, et al. A

multicenter study on the long-term outcomes of halfdose photodynamic therapy in chronic central serous

chorioretinopathy. Am J Ophthalmol. 2016; 170:91-99.

doi:10.1016/j.ajo.2016.07.026.

[14]Zaman M, Mihalache A, Huang RS, et al. Safety and

efficacy of half-dose and half-fluence photodynamic therapy

in chronic central serous chorioretinopathy: a systematic

review and meta-analysis. Am J Ophthalmol. 2025; 271:233-

242. doi:10.1016/j.ajo.2024.11.014.

[15]van Dijk EHC, Fauser S, Breukink MB, et al. Halfdose photodynamic therapy versus high-density subthreshold

micropulse laser treatment in patients with chronic CSC

(PLACE trial). Ophthalmology. 2018; 125(10): 1547-1555.

doi:10.1016/j.ophtha.2018.04.021.

[16]Palakkamanil M, Munro M, Sethi A, Adatia F.

Intravitreal anti-vascular endothelial growth factor for the

treatment of chronic central serous retinopathy: a metaanalysis of the literature. BMJ Open Ophthalmol. 2023; 8(1):

e001310. doi:10.1136/bmjophth-2023-001310.

[17]Schworm B, Luft N, Keidel LF, et al. Response of

neovascular central serous chorioretinopathy to an extended

upload of anti-VEGF agents. Graefes Arch Clin Exp

Ophthalmol. 2020; 258(5): 1013-1021. doi:10.1007/s00417-

020-04623-w.

[18]Daruich A, Matet A, Dirani A, et al. Central serous

chorioretinopathy: recent findings and new physiopathology

hypothesis. Prog Retin Eye Res. 2015; 48:82-118.

doi:10.1016/j.preteyeres.2015.05.003.

[19]Schwartz R, Habot-Wilner Z, Martinez MR, et

al. Eplerenone for chronic central serous chorioretinopathy: a

randomized controlled prospective study. Acta Ophthalmol.

2017; 95(7): e610-e618. doi:10.1111/aos.13491.

[20]Lotery A, Sivaprasad S, O’Connell A, et al.

Eplerenone for chronic central serous chorioretinopathy in

patients with active, previously untreated disease for more

than 4 months (VICI): a randomised, double-blind, placebocontrolled trial. Lancet. 2020; 395:294-303. doi:10.1016/

S0140-6736(19)32981-2.

[21]Nielsen JS, Jampol LM. Oral mifepristone for

chronic central serous chorioretinopathy. Retina. 2011; 31(9):

1928-1936. doi:10.1097/IAE.0b013e31821c3ef6.

[22]Moisseiev E, Holmes AJ, Moshiri A, Morse LS.

Finasteride is effective for the treatment of central serous

chorioretinopathy. Eye (Lond). 2016; 30(6): 850-856.

doi:10.1038/eye.2016.53.

[23]Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh

L, Rafeey M, Ghorbanihaghjo A. The effect of Helicobacter

pylori treatment on remission of idiopathic central serous

chorioretinopathy. Mol Vis. 2011; 17:99-103.

[24]Bahadorani S, Maclean K, Wannamaker K, et

al. Treatment of central serous chorioretinopathy with

topical NSAIDs. Clin Ophthalmol. 2019; 13:1543-1548.

doi:10.2147/OPTH.S202047.

[25]Gramajo AL, Marquez GE, Torres VE, et al.

Therapeutic benefit of melatonin in refractory central serous

chorioretinopathy. Eye (Lond). 2015; 29(8): 1036-1045.

doi:10.1038/eye.2015.104.

[26]刘玉鑫，焦紫曼，邱心悦，等.基于“清阳清窍”

相关学说论治中心性浆液性脉络膜视网膜病变[J/OL].中国

中医眼科杂志. Published online 2025 Nov 3. Available from：

https：//link.cnki.net/urlid/11.2849.R.20250805.1555.005.

[27]曾敏，罗向霞，苏梅贵，等.罗向霞从“脾虚湿

困”论治中心性浆液性脉络膜视网膜病变[J].实用中医

内 科 杂 志.2022；36（8）：44-46，163. doi：10.13729/

j.issn.1671-7813.Z20211380.

[28]陈洋，张南，许家骏，等.利水祛湿法分期治

疗中心性浆液性脉络膜视网膜病经验[J].中华中医药杂

志.2022；37（12）：7201-7204.

[29]苏晓庆，段文娟，李倩茹.激光联合驻景丸加减

治疗中心性浆液性脉络膜视网膜病变[J].中医眼耳鼻喉杂

志.2025；15（3）：158-161.

[30]许伶伶，王俊杰，余赟，等.五苓散加味联合

羟苯磺酸钙治疗中心性浆液性脉络膜视网膜病变临床

研 究[J].浙 江 中 医 杂 志.2024；59（5）：436-437. doi：

10.13633/j.cnki.zjtcm.2024.05.036.


Refbacks

  • 当前没有refback。